PanDx

PanDx — developer of the multifunction catheter Izikat intended for therapy of a serious illness of the digestive tract (DT), including sharp pancreatitis. The device allows to isolate a certain section of a path at simultaneous preserving of passability and maintenance of its basic functions that allows to set a catheter for several days. At the expense of it effective removal of biological liquid is provided for a long time that should improve a status of heavy patients with sharp pancreatitis, intestinal fistulas and holangity, note in the company.

Using a catheter it is also possible to collect biomaterial for diagnosis of oncological diseases of a pancreas and a liver and also for monitoring of diseases of bodies of a GIT.

History

2020: Attraction of 105 million rubles of investments from RBV Capital fund

The RBV Capital fund created with the assistance of RVC and R-Pharm company at the end of December, 2020 invested 105 million rubles in PanDx. Under the terms of the agreement, the investment director of fund Igor Gonikhin will be a part of Board of Directors of a startup.

When the PanDx company according to the results of the transaction and what share in it was received by RBV Capital was estimated, it is not reported. The raised funds will go for performing exploratory clinical trials on patients with sharp pancreatitis and fistulas.

The Russian developer of catheters attracted 105 million rubles to therapy of a serious illness of a GIT of PanDx

For PanDx there is a team of the experienced practicing doctors and management with wide experience in medicine, and we calculate that development will show high efficiency and security during 2021 — Igor Gonikhin said.

By the end of December, 2020 the product PanDx underwent preliminary clinical approbation, patent applications for construction, functionality and application Izikat in diagnostics and treatment of gastrointestinal diseases and a gepatobiliarny system and also in other therapeutic areas were submitted.^[1]

Notes